Abstract
Hypervitaminosis D is a rare reason for hypercalcemia and associated with acute kidney injury. We report on two cases of hypercalcemia and acute kidney injury because of vitamin D intoxication successfully treated with denosumab. Case 1 is an 83-year-old woman, who was initially treated for 2 weeks with intravenous hydration, steroids and thereafter with furosemide without any effect on serum calcium levels and renal function. Because acute renal failure discouraged us to use intravenous bisphosphonate therapy, we applicated 60 mg denusomab subcutaneously. This led to a prompt reduction in serum calcium levels and improvement of renal function within 1 week. Case 2 is a 45-year-old athletic woman, who refused the standard therapy of steroids and forced diuresis for vitamin D intoxication. After 1 day of rehydration therapy, she received 60 mg denusomab. Similar to case 1 serum calcium declined and renal function improved within 7 days.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Araki T, Holick MF, Alfonso BD, et al. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. J Clin Endocrinol Metab. 2011;96(12):3603–8. https://doi.org/10.1210/jc.2011-1443.
Dudenkov DV, Yawn BP, Oberhelman SS, et al. Changing incidence of serum 25-hydroxyvitamin D values above 50 ng/mL: a 10-year population-based study. Mayo Clin Proc. 2015;90(5):577–86. https://doi.org/10.1016/j.mayocp.2015.02.012.
Kolata G. Why are so many people popping vitamin D? The New York Times. https://www.nytimes.com/2017/04/10/health/vitamin-d-deficiency-supplements.html. Published April 10, 2017. Accessed 20 Aug 2020.
Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Ren Physiol. 2005;289(1):F8-28. https://doi.org/10.1152/ajprenal.00336.2004.
Selby PL, Davies M, Marks JS, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol. 1995;43(5):531–6. https://doi.org/10.1111/j.1365-2265.1995.tb02916.x.
Deluca HF, Prahl JM, Plum LA. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys. 2011;505(2):226–30. https://doi.org/10.1016/j.abb.2010.10.012.
Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, Płudowski P, Jones G. Vitamin D toxicity-a clinical perspective. Front Endocrinol. 2018;9:550. https://doi.org/10.3389/fendo.2018.00550.
Jacobs TP, Bilezikian JP. Clinical review: rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005;90(11):6316–22. https://doi.org/10.1210/jc.2005-0675.
Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365(5):410–21. https://doi.org/10.1056/NEJMoa1103864.
Palmer S, Tillman F, Sharma P, et al. Safety of intravenous bisphosphonates for the treatment of hypercalcemia in patients with preexisting renal dysfunction. Ann Pharmacother. 2021;55(3):303–10. https://doi.org/10.1177/1060028020953501.
Wani M, Wani I, Banday K, Ashraf M. The other side of vitamin D therapy: a case series of acute kidney injury due to malpractice-related vitamin D intoxication. Clin Nephrol. 2016;86(11):236–41. https://doi.org/10.5414/CN108904.
Mousseaux C, Dupont A, Rafat C, et al. Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients. Ann Intensive Care. 2019;9(1):133. https://doi.org/10.1186/s13613-019-0606-8.
Sun J, Sun B, Wang W, et al. Histochemical examination of the effects of high-dose 1,25(OH)2D3 on bone remodeling in young growing rats. J Mol Histol. 2016;47(4):389–99. https://doi.org/10.1007/s10735-016-9681-4.
Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol. 2015;11(21):2865–71. https://doi.org/10.2217/fon.15.232.
Bech A, de Boer H. Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med. 2012;156(12):906–7. https://doi.org/10.7326/0003-4819-156-12-201206190-00026.
Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk. 2014;14(6):e207-211. https://doi.org/10.1016/j.clml.2014.07.005.
de Beus E, Boer WH. Denosumab for treatment of immobilization-related hypercalcaemia in a patient with advanced renal failure. Clin Kidney J. 2012;5(6):566–71. https://doi.org/10.1093/ckj/sfs116.
Seiringer E, Prischl FC, Teufel A, Wimmer L, Windpessl M, Wallner M. Acute kidney injury in a patient with multiple sclerosis. Blood Purif. 2020;49:232–53.
Rajan R, Cherian KE, Kapoor N, Paul TV. Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction. Indian J Endocrinol Metab. 2019;23(2):269–70. https://doi.org/10.4103/ijem.IJEM_678_18.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors have declared no conflict of interest.
Informed consent
Informed consent was obtained from patients included in the article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Barth, K., Sedivy, M., Lindner, G. et al. Successful treatment with denosumab for two cases with hypercalcemia due to vitamin D intoxication and associated acute kidney injury. CEN Case Rep 11, 141–145 (2022). https://doi.org/10.1007/s13730-021-00643-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-021-00643-5